Finasteride Tablets 1 mg Recalled for Manufacturing Quality Deviations
Accord Healthcare recalled 1.4 million bottles of Finasteride 1 mg tablets due to manufacturing quality deviations discovered during FDA inspection. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall without reported illnesses or injuries. The hazard is manufacturing process deviations (CGMP non-compliance) discovered during facility inspection, representing potential risk of harm but no confirmed specific contamination or adverse event. Per the rubric, when no illnesses/injuries are reported and the hazard is theoretical, the maximum score is 3.
Plain-English summary
Accord Healthcare, Inc. is recalling 1,440,652 bottles of Finasteride Tablets USP 1 mg in 90-count bottles under the Keeps brand (NDC 71713-096-90). The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations discovered during an FDA inspection of the manufacturing facility.
The affected medication was distributed throughout the United States, including Puerto Rico and Canada. Multiple batch codes are involved, with expiration dates ranging from September 30, 2023, through August 31, 2024. For a complete list of affected batch codes, refer to FDA recall notice D-0391-2023 on the FDA website.
Consumers who have purchased this product should consult their healthcare provider for guidance. The FDA has not reported any illnesses or injuries associated with this recall.
The recalled product
- Product
- Finasteride Tablets USP 1 mg, 90-count bottle, Keeps, Rx Only, Manufactured for: Thirty Madison, Inc. New York, NY 10016 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA, NDC 71713-096-90 UPC 3 71713 09690 2
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 1,440,652
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: P2005583
- P2005584
- P2005585
- P2005527
- P2005528
- P2005586
- Exp. Date 9/30/2023
- P2005980
- Exp. Date 10/31/2023
- P2100396
- P2100264
- P2100263
- Exp. Date 12/31/2023
- P2101583
- P2101711
- P2101708
- P2101584
- Exp. Date 2/29/2024
- P2102852
- P2102851
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same manufacturer · Accord Healthcare, Inc.
See all →- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
Same hazard · quality control failure
See all →- High5-PLASMA Bivalirudin AMR Verification Kit Recalled Due to Stability Issues
FDA (Devices) · 2026-08-12
- HighEXENT Analyser marked plates as passed without performing quality control
FDA (Devices) · 2026-06-17
- HighPreeclampsia growth factor assay recalled over out-of-range quality control values
FDA (Devices) · 2026-04-15
- HighSusceptibility test cards recalled over false resistant antibiotic results
FDA (Devices) · 2026-02-11
- ModerateHeparin control material recalled after quality control results fell below acceptance range
FDA (Devices) · 2025-08-20